PITTSBURGH--(BUSINESS WIRE)--invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its ePRO solutions — DiaryPRO® and SitePRO® — captured primary efficacy data that supported the recent U.S. Food and Drug Administration’s (FDA) supplemental approval of Sucampo Pharmaceutical Inc.’s AMITIZA® (lubiprostone) 8 mcg twice daily for the treatment of irritable bowel syndrome with constipation (IBS-C) in women 18 years of age and older.
